Starling Oncology (STLNW) Gross Profit (2021 - 2026)

Starling Oncology (STLNW) has reported Gross Profit for 6 consecutive years, with $27.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 55.22% year-over-year to $27.2 million; the trailing twelve-month figure through Jun 2026 stood at $297.9 million (up 37.73% YoY), and the FY2025 full-year result was $282.2 million, up 36.62% from the prior year.
• Gross Profit advanced to $27.2 million in Q2 2026 per STLNW's latest filing, from $23.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $228.5 million in Q4 2025 and bottomed at $14.4 million in Q3 2024.
• Historically, Gross Profit has averaged $48.5 million across 5 years, with a median of $30.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Gross Profit soared 346.69% in 2024, then plunged 66.38% in 2025.
• Over 5 years, Gross Profit stood at $33.0 million in 2022, then grew by 13.26% to $37.4 million in 2023, then jumped by 346.69% to $167.2 million in 2024, then soared by 36.69% to $228.5 million in 2025, then sank by 88.11% to $27.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $27.2 million, $23.3 million, and $228.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.